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ABSTRACT The binding of aminoglycoside antibiotics to a broad range of macromolecular targets is coupled to protonation of
one or more of the amino groups that typify this class of drugs. Determining how and to what extent this linkage inﬂuences the
energetics of the aminoglycoside-macromolecule binding reaction requires a detailed understanding of the thermodynamics
associatedwith theprotonation equilibria of the aminoglycoside aminogroups. In recognition of this need, a calorimetric- andNMR-
based approach for obtaining the requisite thermodynamic information is presented using paromomycin as the model
aminoglycoside. Temperature- andpH-dependent 15NNMRstudies provide pKa values for the ﬁveparomomycin amino groups, as
well as the temperature dependence of these pKa values. These studies also indicate that the observed pKa values associatedwith
the freebase formof paromomycin are lower inmagnitude than thecorresponding valuesassociatedwith thesulfate salt formof the
drug. This difference in pKa is due to drug interactionswith the sulfate counterions at the high drug concentrations ($812mM) used
in the 15NNMR studies. Isothermal titration calorimetry studies conducted at drug concentrations#45mM reveal that the extent of
paromomycin protonation linked to the binding of the drug to its pharmacologically relevant target, the 16 S rRNA A-site, is
consistentwith the pKa values of the free base andnot the sulfate salt formof the drug. Temperature- and pH-dependent isothermal
titration calorimetry studies yield exothermic enthalpy changes (DH) for protonation of the ﬁve paromomycin amino groups, as well
as positive heat capacity changes (DCp) for three of the ﬁve amino groups. Regarded as a whole, the results presented here
represent an important ﬁrst step toward establishing a thermodynamic database that can be used to predict how aminoglycoside-
macromolecule binding energetics will be inﬂuenced by conditions such as temperature, pH, and ionic strength. Such a predictive
capability is a critical component of any drug design strategy.
INTRODUCTION
2-Deoxystreptamine (2-DOS)-containing aminoglycosides
are archetypical rRNA-directed antibiotics (1). In addition
to their pharmacologically relevant target, the 16 S rRNA
A-site, 2-DOS aminoglycosides have also been shown to
bind to a broad range of other nucleic acid structures that
adopt A-like conformations, including DNA and RNA tri-
plexes (2–4), DNARNA hybrid duplexes (3–6), and a num-
ber of different RNA structures that function as aptamers
(7–17), ribozymes (18–24), and protein binding sites (25–33).
The interacting macromolecular partners of 2-DOS amino-
glycosides are not restricted to nucleic acids. They also
include proteins. In this connection, the primary mechanism
by which bacteria develop resistance to 2-DOS aminogly-
cosides is through the expression of enzymes that bind to and
covalently modify the drugs (34,35). These aminoglycoside-
modifying enzymes include phosphotransferases, acetyl-
transferases, and nucleotidyltransferases.
Aminoglycosides are typiﬁed by the presence of multiple
primary amine functionalities, which exist in pH-dependent
equilibria between noncharged NH2 and positively charged
NH13 states. A common theme that has emerged from the
structural and biophysical characterizations of aminoglyco-
side-macromolecule interactions that have been reported to
date is the central role that the drug amino groups play in
target recognition. In several instances, aminoglycoside bind-
ing was found to be linked to protonation of at least one drug
amino group (5,33,36–41). Furthermore, this linkage had a
profound inﬂuence on the energetics of the binding reac-
tions. In other words, the energetics of aminoglycoside-
macromolecule interactions are inﬂuenced by the basicities
of the drug amino groups. Determining the nature and mag-
nitude of this inﬂuence requires a detailed thermodynamic
understanding of the protonation equilibrium associated with
each aminoglycoside amino group, which varies in number
from four to six depending on the drug. Toward this end, the
pKa values for the amino groups of a number of different
aminoglycosides have been characterized at a single tem-
perature (38–40,42–47). However, a rigorous thermody-
namic characterization (including DH, DS, DG, DCp, and
DpKa/C) of the protonation equilibria associated with the
multiple amino groups of any aminoglycoside has yet to be
reported. Here, we describe an approach for obtaining the
requisite thermodynamic information using paromomycin, a
2-DOS aminoglycoside that contains ﬁve amino groups (see
structure in Fig. 1), as our model drug. Signiﬁcantly, this
approach, which employs a combination of natural abun-
dance 15N NMR and isothermal titration calorimetry (ITC)
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techniques to derive the relevant information, can be applied
to the characterization of any biomolecule that contains mul-
tiple ionizable amine functionalities.
MATERIALS AND METHODS
RNA and chemicals
The 27-mer RNA oligonucleotide used in this study was obtained in its
PAGE-puriﬁed sodium salt form from Dharmacon Research (Lafayette,
CO). ParomomycinH2SO4 was obtained from Fluka (Milwaukee, WI) and
further treated as described in the next section. The OH form of Amberlite
IRA-400 resin was obtained from Supelco (Bellefonte, PA), whereas the
1.0-N HCl volumetric standard solution used in the calorimetric experiments
was obtained from Aldrich (St. Louis, MO). The 1 M [15N]urea standard in
DMSO was obtained from Isotec (Miamisburg, OH).
Preparation of the free base form of paromomycin
Amberlite IRA-400 resin in its OH form (70 mL) was washed with 350 mL
of water. The washed resin was placed in a glass column 2.5 cm in diameter
and 30 cm in length, and washed with 50 mL of water. A 1.0-mL solution of
0.5 M paromomycinH2SO4 was loaded onto the column. The paromomycin
was then eluted from the column with 200 mL of water at a ﬂow rate of
1 mL/min, and 30-mL fractions were collected. The pH of each fraction
was measured, with the ﬁrst three fractions having a pH . 9.0. These
three fractions were pooled, lyophilized, and stored in their dry state at
20C until used in the NMR and calorimetric studies described below.
Natural abundance 15N NMR spectroscopy
15N NMR spectra were acquired at 30.4 MHz and a temperature of either 25,
35, or 45C on a Varian Unity 300 spectrometer (Palo Alto, CA) using a
recycle delay of 1 s. All 15N chemical shifts are reported relative to NH3
using 1 M [15N]urea in DMSO as an external reference, with the 15N
chemical shift of the reference set to 77.0 ppm. The experimental NMR
solutions were prepared by dissolving at least 300 mg of the lyophilized
paromomycin free base in 600 mL of 85% H2O/15% D2O. The pH of the
NMR samples was adjusted by addition of either HCl or KOH in 85% H2O/
15% D2O. All pH measurements of NMR samples were acquired using a
Corning 430 pH meter (Corning, NY) interfaced with a microstem glass/
calomel combination electrode (Mettler Toledo, Columbus, OH). The
assignments of the 15N resonances for paromomycin were based on those
previously reported (38,43).
Isothermal titration calorimetry
All isothermal calorimetric measurements were conducted on a MicroCal
VP-ITC (MicroCal, Northampton, MA). In the drug protonation experi-
ments (conducted at either 25 or 45C), three 10 mL aliquots of a solution
containing 1 mM HCl and 100 mM KCl were injected from a 250-mL
rotating syringe (300 rpm) into a sample chamber containing 1.42 mL of a
solution containing 2 mM paromomycin in its free base form and 100 mM
KCl (at pH values ranging from 5.53 to 9.40). Each experiment of this type
was accompanied by the corresponding control experiment in which 10 mL
aliquots of 100 mM KCl alone were injected into the relevant solution of
paromomycin and KCl. After three HCl injections, the total change in
solution pH was#0.05 units. Note that all the solutions containing HCl and
KCl were freshly prepared before each experiment using a 1.0-N HCL
volumetric standard solution. The delay between each injection was 420 s,
with the duration of each injection being 10 s. The initial delay before the
ﬁrst injection was 60 s. Each injection generated a heat burst curve (mcal/s
versus s). The area under each heat burst curve was determined by
integration (using the Origin version 7.0 software (MicroCal)) to obtain a
measure of the heat associated with that injection. At any given pH, the heat
associated with each injection of KCl into the drug-KCl mixture was
subtracted from the corresponding heat associated with each injection of
HCl-KCl into drug-KCl to yield the heat of protonation for that injection.
The resulting corrected heats corresponding to the second and third
injections were averaged to yield the observed enthalpy of drug protonation
at that pH.
In the RNA binding experiments (conducted at 25C), 10 mL aliquots of
250 mM paromomycin sulfate were sequentially injected into an RNA
solution that was 10 mM in duplex. Each experiment of this type was
accompanied by the corresponding control experiment in which 10 mL
aliquots of the drug were injected into a solution of buffer alone. The
duration of each injection was 10 s and the initial delay before the ﬁrst
injection was 60 s. The delay between injections was 300 s. The heat
associated with each drug-buffer injection was subtracted from the
corresponding heat associated with each drug-RNA injection to yield the
heat of drug binding for that injection. The resulting corrected injection heats
were plotted as a function of the [drug]/[duplex] ratio and ﬁt with a model for
two independent sets of binding sites. Buffer solutions contained either
FIGURE 1 Structure of paromomycin highlighting (in bold and italics) the ﬁve titratable amino groups. The atomic and ring numbering systems are denoted
in Arabic and Roman numerals, respectively. Ring I of this structure is 2-deoxystreptamine.
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10 mM sodium cacodylate (pH 6.8) or 10 mM TES (pH 6.8), 0.1 mM
EDTA, and sufﬁcient NaCl to bring the total Na1 concentration to 150 mM.
In the sulfate binding experiment (conducted at 25C), 5 mL aliquots of
125 mM paromomycin in its free base form (preadjusted to pH 7.0 by
addition of HCl) were sequentially injected into a 10-mM sodium sulfate
solution. This experiment was accompanied by the corresponding control
experiment in which 5 mL aliquots of the drug were injected into water
alone. The duration of each injection was 5 s and the initial delay before the
ﬁrst injection was 60 s. The delay between injections was 900 s. The heat
associated with each drug-water injection was subtracted from the
corresponding heat associated with each drug-sulfate injection to yield the
heat of drug binding for that injection. The resulting corrected injection heats
were plotted as a function of the [drug]/[sulfate] ratio and ﬁt with a model for
one set of binding sites.
Analysis of the pH dependence of the
ITC-derived enthalpy of drug protonation
At any given value of pH, the fraction (fj) of a given drug amino group (j)
of known pKa that exists in the deprotonated (NH2) state is given by
the Henderson-Hasselbalch relationship:
fj ¼ 1 1
11 10pHpKa
: (1)
The extent (qj) to which the jth amino group becomes protonated as a
result of an HCl injection at a given pH can be described by the derivative
of Eq. 1 with respect to pH:
qj ¼ @fj
@pH
¼ 2:303 10
pHpKa
ð11 10pHpKaÞ2
 
: (2)
Paromomycin has ﬁve ionizable amino groups with differing pKa values.
Thus, the extent of drug protonation (qdrug) that results from an HCl injection
is given by
qdrug ¼ +
5
j¼1
@fj
@pH
 
: (3)
The observed enthalpy of drug protonation (DHprotdrug) at a given pH can
be described by the following equation:
DH
prot
drug ¼ +
5
j¼1
qj
qdrug
DH
prot
j
 
: (4)
In this equation, DHprotj is the enthalpy for protonation of the jth amino
group. The pH-dependent protonation enthalpy data obtained by ITC were
ﬁt with Eq. 4 using the Origin version 7.0 software suite.
RESULTS AND DISCUSSION
Temperature and pH-dependent 15N NMR
characterizations of paromomycin in its
free base form
We monitored the 15N NMR spectrum of paromomycin base
as a function of pH and temperature. Fig. 2 A shows the 15N
NMR spectra of paromomycin base at 25C and three rep-
resentative pH values (3.19, 7.70, and 11.75). The spectrum
at pH 3.19 reﬂects that of the fully protonated form of
paromomycin, with the spectrum at pH 11.75 reﬂecting that
of the fully deprotonated form of the drug. Note that each
amino nitrogen peak shifts upﬁeld with increasing pH, an
observation indicating that each NH2 nitrogen resonates at a
lower frequency than the corresponding NH3 nitrogen. Such
pH-induced upﬁeld shifts of amino nitrogen resonance
frequencies have been previously observed for a number of
different aminoglycosides, including neomycin, lividomy-
cin, tobramycin, gentamicin, kanamycin B, and amikacin
(38,42–45,47). Between pH 3.19 and 7.70, the peaks
FIGURE 2 Temperature and pH dependence of the 15N NMR spectrum of
the free base form of paromomycin. The resonances corresponding to the
ﬁve amino nitrogens are indicated, with the pH- and temperature-induced
shifts of these resonances being denoted by the dashed lines. The 15N
chemical shifts (d) are reported relative to NH3 using 1 M [
15N]urea in
DMSO as an external standard, with the 15N chemical shift of the reference
set to 77.0 ppm. (A) 15N NMR spectra of the free base form of paromomycin
at 25C and pH values of 3.19 (top), 7.70 (middle), and 11.75 (bottom). (B)
15N NMR spectra of the free base form of paromomycin at pH 7.70 and
temperatures of 25C (top) and 45C (bottom).
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corresponding to the 1-, 3-, 29-, and 2%-nitrogens shift
further upﬁeld than the peak corresponding to the 6%-
nitrogen, with the reverse being true between pH 7.70 and
11.75. Thus, the 6%-amino group is more basic than the
other four amino groups, an observation consistent with it
being the only alkyl amine among the ﬁve amino groups.
Fig. 2 B shows the 15N NMR spectra of paromomycin
base at pH 7.70 and temperatures of either 25 or 45C. Note
that the peaks corresponding to the 1-, 29-, and 2%-nitrogens
shift upﬁeld with increasing temperature. These temperature-
induced upﬁeld shifts are indicative of decreased protonation
(i.e., decreased basicity) of the 1-, 29-, and 2%-amino groups
with increasing temperature at pH 7.70, a conclusion veriﬁed
by our temperature-dependent pKa analyses described in the
next section. In contrast to the 1-, 29-, and 2%-nitrogen peaks
at pH 7.70, the 3- and 6%-nitrogen peaks do not undergo a
shift with increasing temperature. One possible interpretation
of this observation is that the basicities of the 3- and 6%-
amino groups are not temperature dependent. An alternative
explanation is that the effects of temperature on the basicities
of the 3- and 6%-amino groups are not detectable at pH 7.70
over the temperature range of 25–45C. As discussed below,
our temperature-dependent pKa analyses support the latter
interpretation.
The pKa values of the ﬁve paromomycin amino
groups decrease with increasing temperature
We monitored the pH dependencies of the 15N chemical
shifts (d) of the ﬁve amino nitrogens of paromomycin base at
25, 35, and 45C, with the resulting pH proﬁles being shown
in Fig. 3, A–C, respectively. Estimates of the pKa values for
the drug amino groups were derived from nonlinear least
squares ﬁts (depicted as solid lines in Fig. 3, A–C) of the pH
proﬁles with the following relationship:
d ¼
dNH13  dNH2
 
10
pHpKa 	
11 10pHpKa
 	 1 dNH13 : (5)
In this relationship, dNH13 and dNH2 are the
15N chemical
shifts of the amino nitrogens in their NH13 and NH2 states,
respectively. The pKa values to emerge from the ﬁts of the
pH proﬁles shown in Fig. 3, A–C, are listed in Table 1. The
corresponding values of dNH13 and dNH2 to emerge from these
ﬁts are summarized in Table S1 of the Supplementary
Material.
Inspection of the data in Table 1 reveals that the pKa
values for all of the amino groups of paromomycin in its free
base form decrease with increasing temperature. Fig. 3 D
graphically depicts these temperature dependencies in the
form of pKa versus temperature plots, which are linear in
nature. The slopes of these linear plots provide quantitative
estimates of DpKa/C for the drug amino groups. Linear
regression analyses of these plots (depicted as solid lines in
Fig. 3 D) yields DpKa/C values that range from 0.023 to
0.029 for the ﬁve amino groups (see Table 1). In other
words, the pKa values of the paromomycin amino groups
decrease by an average of 0.026 pH units per increase in
temperature of 1C. This temperature dependence of pKa for
the paromomycin amino groups implies that the charged state
of paromomycin can vary signiﬁcantly with temperature. As
FIGURE 3 pH dependence of the 15N chemical shifts (d) of the free base
form of paromomycin at 25C (A), 35C (B), and 45C (C). The 15N
chemical shifts are reported as described in the legend to Fig. 2. The
continuous lines reﬂect the calculated ﬁts of the experimental data using Eq.
5. (D) Temperature dependence of the pKa values for the ﬁve paromomycin
amino groups. The experimental data points were ﬁt by linear regression to
yield the solid lines.
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an illustrative example, the pKa values at 25C predict an
average charge of 13.41 for paromomycin base at pH 7.5,
with the predicted average charge at 45C being only 12.50
at the same pH value.
The 15N NMR-derived pKa values associated with
the free base form of paromomycin are lower in
magnitude than the corresponding values
associated with the sulfate salt form of the drug
At 25C, the pKa values of paromomycin base range from
6.50 to 9.13 (see Table 1). We have previously reported (38)
the following 15N NMR-derived pKa values for the sulfate
salt form of paromomycin at 25C: 7.07 for the 3-amino
group, 8.25 for the 2%-amino group, 8.35 for the 29-amino
group, 8.65 for the 1-amino group, and 9.46 for the 6%-
amino group. Note that these pKa values are 0.26–0.57 pH
units higher than the corresponding values for the free base
form of the drug reported here in Table 1, with the difference
in pKa between the two forms of the drug being smallest for
the 29-amino group and largest for the 3-amino group. We
have observed a similar trend when comparing the 15N
NMR-derived pKa values for the sulfate salt and free base
forms of the aminoglycosides neomycin and kanamycin B
(not shown). Taken together, these results indicate that the
presence of sulfate counterions increases apparent amino-
glycoside pKa values determined by natural abundance
15N
NMR. It is likely that this effect is not limited to sulfate
counterions, although the magnitude of the effect may de-
pend on the identity of the counterion.
Calorimetric detection and characterization of interactions
between sulfate ions and the free base form of paromomycin
One potential explanation for the sulfate-induced increase of
the 15N NMR-derived pKa values is the stabilization of the
cationic (NH13 ) forms of the drug amino groups through
electrostatically driven interactions with the sulfate anions.
Such interactions are likely to be weak, but would be favored
at the high drug concentrations ($812 mM) used in the 15N
NMR studies. We probed for such interactions using ITC.
Speciﬁcally, we monitored the observed heat associated with
sequential injection of 125 mM paromomycin (in its free
base form) into a solution of 10 mM sodium sulfate at 25C.
The resulting ITC proﬁle is shown in Fig. 4. Each of the heat
burst curves in panel A of Fig. 4 corresponds to a single
paromomycin injection. Note the nonlinearly decreasing
nature of the heat burst curve peak heights, an observation
consistent with an interaction between the injected drug and
the sulfate ions. The heats derived from integration of the
heat burst curves in Fig. 4 A were corrected for drug dilution
effects as described in the Materials and Methods, with the
resulting corrected injection heats being shown in Fig. 4 B.
These corrected injection heats were ﬁt with a model for one
TABLE 1 15N NMR-derived pKa values for the amino groups
of paromomycin free base at 25, 35, and 45C
Amino
group* pK25Ca pK
35C
a pK
45C
a DpKa/C
y
1 8.20 6 0.07 8.06 6 0.07 7.70 6 0.06 0.025 6 0.006
3 6.50 6 0.03 6.21 6 0.06 6.04 6 0.02 0.023 6 0.001
29 8.07 6 0.04 7.83 6 0.06 7.49 6 0.04 0.029 6 0.003
2% 7.91 6 0.02 7.69 6 0.03 7.38 6 0.02 0.027 6 0.003
6% 9.13 6 0.03 8.89 6 0.04 8.61 6 0.03 0.026 6 0.001
*pKa values were derived from ﬁts of the pH-dependent
15N chemical shift
data shown in Fig. 3 using Eq. 5. The indicated uncertainties reﬂect the
standard deviations of the experimental data from the ﬁtted curves (depicted
as solid lines in Fig. 3).
yValues of DpKa/C were determined by linear regression analyses of the
pKa versus temperature plots shown in Fig. 3 D. The indicated uncertainties
reﬂect the standard deviations of the experimental data from the ﬁtted lines.
FIGURE 4 ITC proﬁle (acquired at 25C and pH 7.0) for the titration of
the free base form of paromomycin into a sodium sulfate solution. Each of
the heat burst curves in panel A is the result of a 5-mL injection of 125 mM
paromomycin, with the sodium sulfate concentration being 10 mM. The
corrected injection heats shown in panel Bwere derived by integration of the
heat burst curves in panel A, followed by subtraction of the corresponding
dilution heats resulting from control titrations of drug into water alone. The
data points in panel B reﬂect the corrected injection heats, while the
continuous line reﬂects the calculated ﬁt of the data using a model for one set
of binding sites.
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set of binding sites (depicted as a solid line in Fig. 4 B). This
ﬁt yielded a binding stoichiometry (N) of 0.44 6 0.02 drug
molecules per sulfate ion. In other words, approximately two
sulfate ions bind to a single drug molecule. Note that each
divalent sulfate anion is capable of interacting with more
than one cationic drug amino group. A second binding pa-
rameter to emerge from the ﬁt of the corrected injection heat
proﬁle shown in Fig. 4 B was a binding enthalpy (DHbind) of
11.2 6 0.1 kcal/mol. This endothermic (unfavorable)
binding enthalpy indicates that the paromomycin-sulfate in-
teraction is entropically driven at 25C, a driving force that
may reﬂect desolvation of the drug and sulfate ions upon
complex formation. A third binding parameter to emerge
from the ﬁt of the injection heat proﬁle shown in Fig. 4 Bwas
an association constant (Ka) of 266 6 15 M
1. This afﬁnity
explains why the presence of sulfate counterions increases
the pKa values determined by
15N NMR, because virtually
every drug molecule is bound by at least one sulfate ion at
the drug concentrations ($812 mM) used in the NMR
studies.
Paromomycin binding to its pharmacologically relevant
target (the 16 S rRNA A-site) is coupled to drug
protonation, with the extent of binding-linked protonation
being consistent with the pKa values determined for the
free base and not the sulfate salt form of the drug
We have previously demonstrated that the binding of 2-DOS
aminoglycosides (including paromomycin) to their pharma-
cologically relevant target, the 16 S rRNA A-site, is linked
to drug protonation (37–40). Given the differences between
the pKa values of the free base and sulfate salt forms of
paromomycin noted above, it is of interest to determine
which set of pKa values is consistent with the observed extent
of RNA binding-linked drug protonation. Toward this end,
we used ITC to determine the observed enthalpies (DHobs)
that accompany the injection of paromomycin sulfate into a
solution containing an E. coli 16 S rRNA A-site model oli-
gonucleotide (schematically depicted in Fig. 5) at pH 6.8 in
the presence of two different buffers (cacodylate and TES)
that exhibit differing heats of ionization (DHion). The number
of drug protons (Dndrug) linked to RNA binding at this pH
can be determined by simultaneous solution of the following
two equations (48,49):
DHobs1 ¼ DHint1DHion1Dndrug (6a)
DHobs2 ¼ DHint1DHion2Dndrug: (6b)
In these equations, the numerical subscripts refer to the
different buffers and DHint is the intrinsic enthalpy, which
differs from DHobs in that it excludes contributions from buf-
fer ionization. Although the value of DHint is independent of
buffer ionization effects, it includes contributions from both
intrinsic drug-RNA interactions and drug-protonation reac-
tions.
The proﬁles resulting from our buffer-dependent ITC
characterizations are shown in Fig. 6. Each of the heat burst
curves in panels A and B of Fig. 6 corresponds to a single
paromomycin injection. The heats derived from integration
of these heat burst curves were corrected for drug dilution
effects as described in the Materials and Methods, with the
resulting corrected injection heats being shown in Fig. 6 C.
Note that the magnitude of the exothermic signal is sub-
stantially greater in cacodylate buffer (DHion ¼ 0.47 kcal/
mol) than in TES buffer (DHion ¼ 17.83 kcal/mol). This
observation is indicative of binding-linked drug protonation,
consistent with our previous results demonstrating such
behavior at pH values .5.5 (37,38). Table 2 lists the DHobs
values derived from ﬁts of the injection heat proﬁles shown
in Fig. 6 C, as well as the corresponding values of Dndrug
and DHint calculated using Eqs. 6a and 6b. Inspection of
these data reveals a Dndrug value of 0.88, indicating that
paromomycin binding is linked to the uptake of 0.88 protons
at pH 6.8. Table 2 also summarizes the protonation states of
paromomycin (expressed as fdrug ¼ fraction of drug amino
groups in their NH2 states) at pH 6.8 predicted by the NMR-
derived pKa values for the free base and sulfate salt forms of
the drug. Note that the pKa values for the sulfate salt predict
that 0.43 out of 5.00 amino groups are deprotonated at pH
6.8. By contrast, the pKa values for the free base form of the
drug predict that 0.83 out of 5.00 amino groups are
deprotonated at this pH. The observed Dndrug value of 0.88
at pH 6.8 is indicative of at least that number of amino
groups being deprotonated in the unbound (RNA-free) state
of the drug. This state of deprotonation is inconsistent with
that predicted by the pKa values of the sulfate salt. In other
words, the observed value ofDndrug for the paromomycin-RNA
FIGURE 5 NMR-derived (53–55) secondary structure of the E. coli 16 S
rRNA A-site model oligonucleotide used in this study. Watson-Crick
basepairs are denoted by solid lines, whereas mismatched basepairs are
denoted by dashed lines. Bases present in E. coli 16 S rRNA are depicted in
bold face, and are numbered as they are in 16 S rRNA. The paromomycin
binding site, as revealed by NMR and footprinting studies (53,54,56), is
indicated.
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interaction is consistent with the pKa values of the free base
and not the sulfate salt form of the drug, even though the
sulfate salt form of the drug was used in the RNA binding
ITC experiments. Recall that the 15N NMR-derived pKa
values for the sulfate salt form of paromomycin were higher
than the corresponding values for the free base form of the
drug due to interactions between the sulfate ions and the drug
amino groups. In addition, these interactions were associated
with a Ka value of 266 M
1. Note that the concentration of
paromomycin sulfate used in the RNA binding ITC exper-
iments ranged from 0 to 45 mM, a range of concentrations at
least 18,000-fold lower than that used in the 15N NMR exper-
iments. Over the range of paromomycin sulfate concentra-
tions used in the ITC studies, the drugmolecules are essentially
free of sulfate interactions (given the Ka value of 266 M
1
we observed for the sulfate-drug interactions), and thus
behave like the free base. It is also important to note that the
RNA binding ITC studies were conducted in the presence of
150 mM Na1, as compared to 20 mM Na1 in the sulfate
binding ITC study. With the reasonable assumption that the
binding of paromomycin to sulfate ions is electrostatically
driven and therefore salt sensitive, the Ka value for the
sulfate-drug interactions in the presence of 150 mM Na1
should be ,266 M1. This reduction in Ka would serve to
further reduce the already low degree of sulfate-drug inter-
actions that occur over the range of drug concentrations used
in the RNA binding ITC studies.
The observed enthalpy of paromomycin
protonation varies with pH
We used ITC to determine the enthalpy of paromomycin
protonation. Fig. 7 shows representative ITC data obtained at
25C for three sequential 10-mL injections of 1 mMHCl into
a 1-mM solution of paromomycin base at either pH 7.00
(panel A) or pH 8.45 (panel B). Each heat burst curve in Fig.
7 corresponds to a single HCl injection. Inspection of these
ITC data reveals the following signiﬁcant features: i), the
heat burst curves at both values of pH are exothermic in
nature, an observation indicating that at least one drug amino
group has an exothermic protonation enthalpy (DHprot) at
25C. ii), At each pH value, the intensity of the exothermic
signal corresponding to the ﬁrst injection is smaller in
magnitude than the signals corresponding to the second and
third injections. The comparatively small magnitude of the
signal corresponding to the ﬁrst injection is a commonly
observed phenomenon in ITC experiments, and is instru-
mental in origin. iii), At each pH value, the intensities of the
exothermic signals corresponding to the second and third
injections are similar in magnitude. This observation is con-
sistent with all the protons from the injected HCl binding to
the drug under the conditions employed. iv), The magnitudes
of the exothermic signals are greater at pH 8.45 than at pH
7.00. This result implies that the value of DHprot for one or
more of the drug amino groups differs in magnitude from the
FIGURE 6 ITC proﬁles (acquired at 25C and pH 6.8) for the titration of
paromomycin sulfate into a solution containing the E. coli 16 S rRNA A-site
model oligonucleotide in cacodylate (A) and TES (B) buffer. Each of the heat
burst curves in panels A and B is the result of a 10-mL injection of 250-mM
paromomycin sulfate, with the RNA concentration being 10-mM in duplex.
The corrected injection heats shown in panel C were derived by integration
of the heat burst curves in panels A and B, followed by subtraction of the
corresponding dilution heats resulting from control titrations of drug into
buffer alone. The data points in panel C reﬂect the corrected injection heats,
whereas the continuous lines reﬂect the calculated ﬁts of the data using
a model for two sets of binding sites. Each experimental solution contained
10 mM buffer, 0.1 mM EDTA, and sufﬁcient NaCl to bring the total Na1
concentration to 150 mM.
1344 Barbieri and Pilch
Biophysical Journal 90(4) 1338–1349
corresponding values of DHprot for the other amino groups.
In other words, the pH-induced change in the observed heat
of drug protonation reﬂects proton binding to two or more
amino groups with differing protonation enthalpies.
The ITC data shown in Fig. 7, as well as corresponding
data (not shown) acquired at 25C and other values of pH
(ranging from 6.22 to 9.40), were analyzed as described in
the Materials and Methods to yield the observed enthalpies
of drug protonation (DHprotdrug) depicted by the solid circles in
Fig. 8. In addition, Fig. 8 also shows the corresponding pH
dependence of DHprotdrug at 45C (depicted by the open circles).
At both temperatures, increasing pH results in an initial
decrease in DHprotdrug followed by an increase. Note that the pH
at which DHprotdrug reaches a minimum is;1 unit lower at 45C
than at 25C. This observation is consistent with our
temperature-dependent 15N NMR results, which revealed
an inverse relationship between temperature and the pKa of
each paromomycin amino group (see Fig. 3 and Table 1).
Further note that, at any given pH, the value of DHprotdrug at
45C is less exothermic than the corresponding value of
DHprotdrug at 25C. This result implies that the DH
prot value of at
least one drug amino group is temperature dependent, with
increasing temperature resulting in a less exothermic value of
DHprot. In this connection, our heat capacity change deter-
minations discussed below reveal that three paromomycin
amino groups exhibit such a behavior.
Protonation of the ﬁve paromomycin amino
groups is associated with an exothermic
enthalpy change, the magnitude of which is not
correlated with pKa
The pH-dependent DHprotdrug proﬁles shown in Fig. 8 were ﬁt
with Eq. 4 to yield quantitative estimates of the DHprot values
for the ﬁve paromomycin amino groups. The resulting values
ofDHprot are listed in Table 3. Note that protonation of all ﬁve
amino groups is exothermic, with DHprot values at 25C
ranging from 5.4 kcal/mol (for the 2%-amino group) to
15.8 kcal/mol (for the 1-amino group). This range of DHprot
values is consistent with the range of previously reported
protonation enthalpies for the amino groups of numerous
different types of amine derivatives, including glucosamines,
alkylamines, phenylamines, and amino acids (50). Further note
that the uncertainties (which range from ;18 to 43%)
associated with the DHprot values of the 1-, 29-, and 2%-amino
groups are substantively greater than the corresponding uncer-
tainties (of ;1%) associated with the DHprot values of the
3- and 6%-amino groups. The comparatively large uncer-
tainties associatedwith theDHprot values of the 1-, 29-, and 2%-
amino groups stem from the similar pKa values of these three
groups, which are all within ;0.3 pH units of each other. A
comparison of the DHprot data in Table 3 with the cor-
responding pKa data in Table 1 reveals that the magnitude of
DHprot does not correlate with the basicity (i.e., pKa) of the
TABLE 2 Number of protons linked to the binding of paromomycin to the E. coli 16 S rRNA A-site model oligonucleotide at pH 6.8
Buffer (10 mM) DHion* (kcal/mol) DHobs
y (kcal/mol) DHint
z (kcal/mol) Dndrug
z fdrug
§ (Sulfate salt) fdrug
§ (Free base)
Cacodylate 0.47 12.5 6 0.1 12.1 6 0.1 0.88 6 0.03 0.43 6 0.01 0.83 6 0.03
TES 17.83 5.2 6 0.1
*Ionization heats (DHion) at 25C for the indicated buffers were taken from Fukada and Takahashi (52).
yDHobs values were derived from ﬁts of the ITC proﬁles shown in Fig. 6 C, with the indicated uncertainties reﬂecting the standard deviations of the
experimental data from the ﬁtted curves.
zValues of DHint and Dndrug were determined using Eqs. 6a and 6b, with the indicated uncertainties reﬂecting the maximum errors in DHobs as propagated
through these equations.
§Values of fdrug were calculated from the
15N NMR-derived pKa values for the sulfate salt and free base forms of paromomycin using the Henderson-
Hasselbalch relationship: fdrug ¼ 5+5j¼1ðð1=1110pHpKaj ÞÞ. In this relationship, pKaj is the pKa value for the jth amino group. The indicated uncertainties
in fdrug reﬂect the maximum errors in the NMR-derived pKa values as propagated through the above relationship.
FIGURE 7 ITC heat burst curves resulting from
10mL injections of 1 mMHCl into a solution containing
2 mM of paromomycin in its free base form at 25C
and pH values of 7.00 (A) and 8.45 (B). All experiments
were conducted in the presence of 100 mM KCl.
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amino group. As an illustrative example, the DHprot values of
the 6%- and3-amino groups at 25Care similar (9.4 and9.0
kcal/mol, respectively). By contrast, the pKa values of these
two groups at 25C differ markedly from one another (9.13 for
the 6%-amino group versus 6.50 for the 3-amino group).
Deﬁning the heat capacity changes for
protonation of the paromomycin amino groups
The heat capacity change associated with a protonation reac-
tion (DCprotp ) can be determined from the temperature de-
pendence of the protonation enthalpy. To this end, the values
of DHprot determined at 25 and 45C enabled us to determine
DCprotp for the ﬁve paromomycin amino groups using the
following standard relationship:
DC
prot
p ¼
DH
prot
T1
 DHprotT2
T1  T2 : (7)
The resulting values of DCprotp are listed in Table 3. In-
spection of these data reveals that the heat capacity changes
for protonation of the 1-, 3-, and 6%-amino groups are positive
and range from 38 6 4 cal/mol K (for protonation of the
3-amino group) to 3926 244 (for protonation of the 1-amino
group). The positive DCprotp values for these three amino
groups account for the less exothermic nature of the DHprotdrug
versus pH proﬁle acquired at 45C relative to that acquired at
25C (see Fig. 8). Furthermore, the signs and magnitudes of
these DCprotp values are consistent with those predicted for
charge-transfer (e.g., protonation) reactions based on the
Poisson-Boltzmann equation (51). Note that the observed
DCprotp values for the 29- and 2%-amino groups are negative.
However, the magnitudes of these values are sufﬁciently
small so as to fall within the experimental uncertainty. Thus,
the uncertainty of our data does not permit us to accurately
deﬁne the DCprotp values for the 29- and 2%-amino groups,
even though these values, like those for the 1-, 3-, and 6%-
amino groups, may be nonzero.
Completing the thermodynamic proﬁles for
protonation of the paromomycin amino groups
Armed with the NMR-derived pKa values listed in Table 1,
we calculated the corresponding free energies of protonation
(DGprot) using the following relationship:
DG
prot ¼ RT lnð10pKaÞ: (8)
These protonation free energies, coupled with the ITC-
derived protonation enthalpies listed in Table 3, allowed us
to calculate the corresponding protonation entropies (DSprot)
using the standard relationship
DSprot ¼ DH
prot  DGprot
T
: (9)
Application of Eqs. 8 and 9 enabled us to generate
complete thermodynamic proﬁles for protonation of the ﬁve
paromomycin amino groups, with the resulting proﬁles at
25C being listed in Table 4. Protonation of all ﬁve amino
groups is enthalpically favorable (i.e., all ﬁve DHprot values
are exothermic). However, the nature and magnitude of the
entropic forces associated with protonation depend on the
identity of the amino group. For the 3- and 29-amino groups,
the protonation entropies are essentially zero, with the dif-
ferences between the determined values of DSprot and zero
being within the experimental uncertainty. In other words,
protonation of these two amino groups is entropically neu-
tral. In contrast to the values of DSprot for the 3- and 29-amino
groups, the corresponding values for the 1-, 2%-, and 6%-
amino groups are nonzero, with DSprot being negative for the
1-amino group and positive for the 2%- and 6%-amino
groups. Thus, protonation of the 1-amino group is entropi-
cally unfavorable, while being entropically favorable for the
2%- and 6%-amino groups. Regarded as a whole, these
observations indicate that protonation of the 1-, 3-, and 29-
amino groups is driven by enthalpic forces, which overcome
FIGURE 8 pH dependence of the observed protonation enthalpy of
paromomycin (DHprotdrug) in its free base form acquired at 25C (d) and 45C
(s). Values of DHprotdrug were derived from ITC experiments similar to and
including those shown in Fig. 7 using an approach detailed in Materials and
Methods. The continuous lines reﬂect the calculated ﬁts of the data using Eq. 4.
TABLE 3 Temperature dependent enthalpy and
corresponding heat capacity changes for protonation
of the ﬁve paromomycin amino groups
Amino group
DHprot25C*
(kcal/mol)
DHprot45C*
(kcal/mol)
DCprotp
y
(cal/mol K)
1 15.8 6 3.4 7.9 6 1.4 1392 6 244
3 9.0 6 0.1 8.2 6 0.1 138 6 4
29 11.5 6 5.0 12.7 6 3.6 58 6 430
2% 5.4 6 1.7 7.3 6 2.2 93 6 199
6% 9.4 6 0.1 8.4 6 0.1 148 6 12
*Values of DHprot were derived from ﬁts of the pH-dependent DHprotdrug
proﬁles shown in Fig. 8 using Eq. 4. The indicated uncertainties reﬂect the
standard deviations of the experimental data from the ﬁtted curves.
yValues of DCprotp were determined using Eq. 7 and the DH
prot values listed
in columns 2 and 3. The indicated uncertainties reﬂect the maximum errors
in the values of DHprot as propagated through the Eq. 7.
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neutral or unfavorable entropic forces. By contrast, proton-
ation of the 2%- and 6%-amino groups is driven by positive
contributions from both enthalpic and entropic forces, with
the relative contributions being ;50% enthalpic/50% entro-
pic for the 2%-amino group and 75% enthalpic/25% entropic
for the 6%-amino group.
Validation of our calorimetrically derived values
DHprot for the ﬁve paromomycin amino groups
at 25 and 45C
As noted in a previous section, the similar pKa values of the
1-, 29-, and 2%-amino groups cause our calorimetrically
derived values of DHprot for these amino groups at 25 and
45C to be associated with a greater of degree of uncertainty
than the corresponding DHprot values for the 3- and 6%-
amino groups. These differential uncertainties in DHprot were
conferred upon our calculated values of DCprotp , because the
DHprot values acquired at 25 and 45C were used to calculate
DCprotp via Eq. 7. Given these uncertainties, we sought to
validate our experimental values of DHprot (and thus DCprotp
as well) by using them to calculate theoretical pKa values at
35C, and subsequently comparing these calculated pKa
values with our corresponding NMR-derived values. To this
end, we used the calorimetrically derived DHprot and DCprotp
values listed in Table 3, coupled with the NMR-derived pKa
values at 25C listed in Table 1, to calculate theoretical pKa
values at 35C for the ﬁve paromomycin amino groups uti-
lizing the following expression:
pK
T2
a ¼ pKT1a 1 0:435
1
T2
 1
T1
  DHprotT1 1 T1DCprotp
R
 
1
DC
prot
p
R
log
T2
T1
 
: (10)
In our application of this expression, T1 ¼ 25C (298.15
K) and T2 ¼ 35C (308.15 K). The resulting calculations
yielded the following pKa values at 35C: 7.876 0.11 for the
1-amino group; 6.29 6 0.01 for the 3-amino group; 7.79 6
0.17 for the 29-amino group; 7.77 6 0.06 for the 2%-amino
group; and 8.91 6 0.01 for the 6%-amino group. These
calculated pKa values at 35C are in good agreement with the
corresponding NMR-derived values listed in Table 1, the
differences being within the collective uncertainties. This
gratifying concordance validates not only our calorimetri-
cally derived values of DHprot and DCprotp , but also our
delineation of the thermodynamic forces that govern the drug
protonation reactions.
CONCLUDING REMARKS
We have used natural abundance 15N NMR and ITC to
determine complete thermodynamic proﬁles (DH, DS, DG,
DCp, pKa, and DpKa/C) for the ﬁve protonation equilibria of
the 2-DOS aminoglycoside paromomycin. To the best of our
knowledge, this study represents the ﬁrst such thermody-
namic characterization of the pH and temperature-dependent
properties of an aminoglycoside antibiotic. Signiﬁcantly, the
approach presented here can be applied to the characteriza-
tion of any compound or biomolecule that contains multiple
ionizable groups.
The linkage of drug protonation reactions to the interac-
tions between drugs and macromolecules can have a
profound effect on the observed binding thermodynamics.
The afﬁnities of aminoglycosides for a broad range of nucleic
acid targets have been shown to decrease with increasing pH
(5,33,36–38). In addition, this pH dependence of the binding
energetics was shown to result from the linkage of drug
protonation reactions to formation of the drug-nucleic acid
complexes. Note that aminoglycoside protonation reactions
are not only linked to the interactions between these drugs
and nucleic acids, but also to the interactions of the drugs with
modifying enzymes, which confer resistance to the microbes
that carry them. In this connection, the Serpersu group has
demonstrated that drug protonation reactions are linked to
the binding of aminoglycosides to a phosphotransferase en-
zyme (41).
The type of pKa and thermodynamic information presented
here is essential for understanding the nature of the linkage
between drug-macromolecule binding and drug protonation,
as well as the thermodynamic consequences of that linkage.
In particular, such information enables one to: i), identify
the speciﬁc amino groups whose protonation is linked to the
binding interaction; ii), deﬁne the contributions that the
relevant protonation reactions make to the observed binding
thermodynamics; and iii), predict how the binding energetics
will be affected by environmental conditions, such as tem-
perature, pH, and ionic strength. Such capabilities are impor-
tant elements of any rational drug design strategy.
SUPPLEMENTARY MATERIAL
An online supplement to this article can be found by visiting
BJ Online at http://www.biophysj.org.
TABLE 4 Thermodynamic proﬁles for protonation of the ﬁve
paromomycin amino groups at 25C
Amino group
DHprot*
(kcal/mol)
DSproty
(cal/mol K)
DGprotz
(kcal/mol)
1 15.8 6 3.4 15.4 6 11.7 11.2 6 0.1
3 9.0 6 0.1 10.3 6 1.0 8.9 6 0.1
29 11.5 6 5.0 1.7 6 17.1 11.0 6 0.1
2% 5.4 6 1.7 118.1 6 6.0 10.8 6 0.1
6% 9.4 6 0.1 110.4 6 0.7 12.5 6 0.1
*Values of DHprot were determined as described in the footnote to Table 3.
yValues of DSprot were determined using Eq. 9 and the corresponding
values of DHprot and DGprot. The indicated uncertainties reﬂect the max-
imum errors in DHprot and DGprot as propagated through Eq. 9.
zValues of DGprot were determined using Eq. 8 and the corresponding
NMR-derived value of pKa. The indicated uncertainties reﬂect the
maximum errors in pKa as propagated through Eq. 8.
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